Oncotartis in collaboration with scientists from the Children’s Cancer Institute of Australia for Medical Research (CCIA) initiated testing of OT-82 in systemic preclinical models based on patient-derived cells from pediatric ALL patients with rearranged Mixed Lineage Leukemia gene.